FDA authorizes Omicron-specific boosters
The U.S. Food and Drug Administration on Wednesday authorized updated, Omicron-specific COVID-19 boosters from both Pfizer and Moderna, multiple outlets report.
The new shots are expected post-Labor Day, pending review from the Centers for Disease Control and Prevention later this week, notes The Washington Post. The boosters' bivalent formula targets both the BA.4 and BA.5 Omicron subvariant, as well as the original strain of the virus that circulated back in 2020.
The agency notably cleared the jabs without data from human trials, which it argued could detrimentally slow the process and perhaps render moot any data used in authorization, per The New York Times.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Pfizer's booster was cleared for use in individuals ages 12 and up, while the Moderna shot was authorized for those 18 and older. Prospective recipients must wait at least two months after finishing their primary series of vaccinations or after receiving their last booster dose to get the new shot.
"As we head into fall and begin to spend more time indoors, we strongly encourage anyone who is eligible to consider receiving a booster dose," FDA Commissioner Robert Califf said Wednesday.
The Biden administration is preparing to distribute the shots as part of its fall booster campaign, NBC News adds.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.
-
Is the ceasefire in Gaza really working?Today's Big Question Neither Israel and Hamas has an interest in a full return to hostilities but ‘brutally simple arithmetic’ in region may scupper peace plan long-term
-
Are boomers the real phone addicts?In The Spotlight There’s an ‘explosion in screentime’ among older people – and they’re more vulnerable to misinformation
-
West End Girl: a ‘tremendously touching’ break-up albumThe Week Recommends Lily Allen’s unfiltered new work is ‘littered with relatable moments’
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
